CD274 and cervical carcinoma: Notably, in Japan, first‐line treatment with pembrolizumab for metastatic cervical cancer is not limited by programmed cell death‐ligand 1 (PD‐L1) expression status, unlike in Europe and the United States where pembrolizumab is only approved for patients with PD‐L1 expression ≥ 1%.22, 23, 24